Waystar Holding Corp. Common Stock
WAY
$25.01
+0.68%
Waystar Holding Corp. is a provider of mission-critical cloud technology for healthcare organizations, specializing in streamlining the complex payment processes between providers, payers, and patients. As a key player in the healthcare information services industry, Waystar differentiates itself through its enterprise-grade platform that enhances data integrity, reduces manual tasks, and improves claim accuracy, thereby accelerating reimbursement cycles. The current investor narrative centers on the company's robust revenue growth and expanding margins, yet the stock has faced significant volatility since its mid-2024 IPO, with a sharp decline from its 52-week high and a recent recovery attempt. Attention is focused on Waystar's ability to sustain its growth trajectory, integrate acquisitions, and navigate competitive pressures in the healthcare technology space.…
WAY
Waystar Holding Corp. Common Stock
$25.01
Investment Opinion: Should I buy WAY Today?
Based on the analysis, WAY is rated a Buy. The consensus Strong Buy rating from 23 analysts, with an average target price of $33.22 (39.8% upside), supports this view. The thesis is that Waystar's accelerating revenue growth (24.35% YoY) and expanding margins (net margin up to 10.2%) will drive earnings growth, making the forward PE of 12.65x attractive.
Sign up to view all
WAY 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The accelerating revenue growth and improving margins provide a strong fundamental foundation, while the forward valuation is attractive. However, the stock's high volatility and underperformance relative to the market warrant caution. The key risk is whether the company can meet the high earnings expectations embedded in the forward PE. If Waystar delivers on its growth promises, the stock could recover significantly. Monitoring points include quarterly earnings, margin trends, and any changes in analyst sentiment.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Waystar Holding Corp. Common Stock's 12-month outlook, with a consensus price target around $33.17 and implied upside of +32.6% versus the current price.
Average Target
$33.17
0 analysts
Implied Upside
+32.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$27 - $44
Analyst target range
Waystar is covered by 23 analysts, with a consensus recommendation of 'Strong Buy' and a mean recommendation score of 1.29 (where 1 is Strong Buy and 5 is Sell). The average target price is $33.22, implying an upside of approximately 39.8% from the current price of $23.77. The distribution of ratings is heavily skewed toward bullish, with no Hold or Sell ratings reported, indicating strong conviction among analysts. Recent actions from major firms like Deutsche Bank, Wells Fargo, and Goldman Sachs have been reaffirmations of Buy or Overweight ratings, with one upgrade from Hold to Buy by Freedom Capital Markets, signaling positive sentiment.
Bulls vs Bears: WAY Investment Factors
Waystar presents a compelling bull case with accelerating revenue growth (24.35% YoY), strong analyst conviction (Strong Buy, 39.8% upside), and improving profitability (net margin up to 10.2%). However, the bear case is equally strong, highlighted by a 57.67% drawdown from highs, a high trailing PE of 51.98x, and persistent underperformance versus the market. The single most important tension is whether the company can sustain its growth trajectory and margin expansion to justify the forward PE of 12.65x, or if the recent volatility signals deeper operational challenges. Currently, the bull case has stronger evidence due to the accelerating growth and analyst support, but the stock's price action suggests the market remains skeptical. The resolution of this tension will determine whether WAY can recover to analyst targets or continue to slide.
Bullish
- Accelerating Revenue Growth: Q4 2025 revenue grew 24.35% YoY to $303.5M, up from 21.5% growth in Q3 2025. This acceleration indicates strong market adoption and successful execution of the growth strategy.
- Strong Analyst Conviction: 23 analysts rate WAY a Strong Buy with a mean score of 1.29 (1=Strong Buy). No Hold or Sell ratings exist, and the average target price of $33.22 implies ~39.8% upside from the current price.
- Improving Profitability: Net margin expanded to 10.2% in Q4 2025 from 7.8% in Q4 2024, and operating margin rose to 25.0% from 21.8%. This trend shows operational leverage and cost discipline.
- Recurring Revenue Base: Subscription and circulation revenue reached $167.8M in Q4 2025, representing 55% of total revenue. This recurring stream provides visibility and stability to future cash flows.
Bearish
- Severe Post-IPO Drawdown: WAY has fallen 57.67% from its 52-week high of $41.47 to $23.77, and is down 31.4% over the past year. This persistent downtrend signals waning investor confidence and potential structural issues.
- High Trailing Valuation: The trailing PE of 51.98x is steep, indicating the stock was priced for perfection. If earnings growth disappoints, the multiple could contract sharply, leading to further downside.
- Negative Relative Strength: WAY underperformed the S&P 500 by 53.6% over the past year and by 37.3% year-to-date. This persistent underperformance suggests the market is pricing in higher risk or lower growth prospects.
- Elevated Debt Levels: Debt-to-equity stands at 0.38, and interest expense was $25.3M in Q4 2025, consuming a significant portion of operating income. High leverage could strain cash flows if growth slows.
WAY Technical Analysis
Waystar's price trend over the past year has been predominantly downward, with a 1-year price change of -31.4%, reflecting a sustained downtrend from its IPO highs. The current price of $23.77 sits at approximately 57.3% of its 52-week range (between $17.26 low and $41.47 high), indicating the stock is closer to the lower end of its range, which could suggest a value opportunity or a falling knife depending on fundamental support. The stock's beta of 0.058 implies it is significantly less volatile than the broader market, which is unusual for a recent IPO and may indicate limited correlation with market movements.
Beta
0.06
0.06x market volatility
Max Drawdown
-57.7%
Largest decline past year
52-Week Range
$17-$41
Price range past year
Annual Return
-30.0%
Cumulative gain past year
| Period | WAY Return | S&P 500 |
|---|---|---|
| 1m | +20.3% | +3.6% |
| 3m | +27.8% | +2.7% |
| 6m | -0.2% | +11.4% |
| 1y | -30.0% | +18.7% |
| ytd | -20.3% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WAY Fundamental Analysis
Waystar's revenue trajectory shows strong growth, with the most recent quarter (Q4 2025) reporting revenue of $303.5 million, a 24.35% year-over-year increase. This growth is accelerating, as Q3 2025 revenue was $268.7 million (up from $240.1 million in Q3 2024), and Q2 2025 revenue was $270.7 million (up from $234.5 million in Q2 2024). The company's subscription and circulation segment contributed $167.8 million in the latest quarter, indicating a recurring revenue base. The growth is driven by increased adoption of its cloud platform and successful acquisitions, positioning Waystar as a consolidator in the healthcare payments space.
Quarterly Revenue
$303538000.0B
2025-12
Revenue YoY Growth
+24.3%
YoY Comparison
Gross Margin
56.2%
Latest Quarter
Free Cash Flow
$283192000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WAY Overvalued?
Given that Waystar has positive net income (EPS of $0.10 in Q4 2025), the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 51.98x, while the forward PE is 12.65x, implying the market expects significant earnings growth in the coming year. The wide gap between trailing and forward PE suggests that analysts anticipate a substantial increase in earnings, likely driven by margin expansion and revenue growth. This forward multiple is more reasonable for a high-growth healthcare technology company, but the trailing multiple indicates that the stock has historically been priced for perfection.
PE
52.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 54x~83x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant. WAY carries a debt-to-equity ratio of 0.38, and interest expense of $25.3M in Q4 2025 consumed about 33% of operating income. While the company is now profitable, its net margin of 10.2% is thin, leaving little room for error. The high trailing PE of 51.98x implies that any earnings miss could trigger a sharp de-rating. Additionally, free cash flow of $283.2M TTM is positive, but the company's reliance on acquisitions for growth (as seen in revenue growth) could strain cash reserves if integration costs rise.